Notably, we demonstrated that both high-MAL gene expression and low-VILL gene expression seem to synergistically confer survival advantages for patients with melanoma, lung adenocarcinoma, pancreatic adenocarcinoma, or renal cancer (Figure 3B). The gene discussed is MAL; the disease is renal carcinoma.